Advanced medullary thyroid cancer: pathophysiology and management

about

Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer.Arriving at the Right Diagnosis in an Era of Precision Medicine.Medullary carcinoma of the thyroid with axillary metastasis: a case report.

P2860

Q38630967-8FD572D9-3C4F-46AB-B933-D4E096DC17D8 Q41388736-76371CB6-2CBC-4990-987E-1FF0DAF62602 Q43198576-2B30E385-C86F-48DB-B774-769E66DD0736

P2860

Advanced medullary thyroid cancer: pathophysiology and management

Item

http://www.wikidata.org/entity/Q36857218

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Advanced medullary thyroid cancer: pathophysiology and management

@en

type

Item

label

Advanced medullary thyroid cancer: pathophysiology and management

@en

prefLabel

Advanced medullary thyroid cancer: pathophysiology and management

@en

P1476

Advanced medullary thyroid cancer: pathophysiology and management

@en

P2093

Carla Vaz Ferreira

http://www.w3.org/2001/XMLSchema#string

Débora Rodrigues Siqueira

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

Anti-tumor activity of motesanib in a medullary thyroid cancer model.

Cell signaling by receptor tyrosine kinases

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Characterization of the ret proto-oncogene products expressed in mouse L cells

Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties.

P304

57-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S33105

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ana Luiza Maia

Lucieli Ceolin

P577

2013-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236930650

http://www.w3.org/2001/XMLSchema#string

P698

23696715

http://www.w3.org/2001/XMLSchema#string

P932

3658436

http://www.w3.org/2001/XMLSchema#string

Advanced medullary thyroid cancer: pathophysiology and management

about

P2860

P2860

Advanced medullary thyroid cancer: pathophysiology and management

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P5875

P698

P932